{"nctId":"NCT02673151","briefTitle":"68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment","startDateStruct":{"date":"2017-05-20","type":"ACTUAL"},"conditions":["Prostate Adenocarcinoma","PSA Failure","Recurrent Prostate Carcinoma"],"count":61,"armGroups":[{"label":"68Ga-PSMA-11 PET/CT","type":"EXPERIMENTAL","interventionNames":["Procedure: Computed Tomography (CT) scan","Drug: 68Ga-PSMA-11","Procedure: Positron Emission Tomography (PET)"]}],"interventions":[{"name":"Computed Tomography (CT) scan","otherNames":["Computerized Axial Tomography (CAT)","CAT scan","Computed Tomography (CT)","Computerized Tomography (CT)","CT Scan","tomography"]},{"name":"68Ga-PSMA-11","otherNames":["68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11)","68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC","68Ga-HBED-CC-PSMA","HBED-CC-PSMA","DFKZ-11","Heidelberg compound"]},{"name":"Positron Emission Tomography (PET)","otherNames":["Positron Emission Tomography scan (PET-scan)","Proton magnetic resonance spectroscopic imaging"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histopathological proven prostate adenocarcinoma\n* Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy)\n\n  * Post radical prostatectomy (RP) - American Urology Association (AUA) recommendation\n\n    * PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP\n    * Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL)\n  * Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix consensus definition\n\n    * A rise of PSA measurement of 2 or more ng/mL over the nadir\n* Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group \\[ECOG\\] / World Health Organization \\[WHO\\] equivalent)\n* Able to provide written consent\n\nExclusion Criteria:\n\n* Investigational therapy for prostate cancer.\n* Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.\n* Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT","description":"Participants had suspected prostate cancer recurrence, and were evaluated with 68Ga-PSMA-11 PET/CT and by conventional methodologies, eg, histopathology/biopsy and/or conventional imaging. The outcome will be reported as the percentage of participants for whom the 68Ga-PSMA-11 PET/CT scan was positive (confirmed by conventional methodologies) or negative (not confirmed by conventional methodologies). The outcome is reported as the number of participants without dispersion. Up to 1 year was allowed for result by the conventional methodology.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"68Ga-PSMA-11 PET/CT Sensitivity and Specificity","description":"68Ga-PSMA-11 PET/CT sensitivity and specificity were assessed by comparing 68Ga-PSMA-11 PET/CT scan results with conventional imaging follow-up and/or histopathology/biopsy within the following 1 year. Sensitivity is a percentage that estimates, within a group of participants, the proportion within that group that truly has a disease or condition. Specificity is a percentage that estimates, within a group of participants, the proportion within that group that truly does not have the disease or condition. The outcome is reported as the point estimates for sensitivity and specificity, given as percentages representing agreement between the 68Ga-PSMA-11 PET/CT scan result and the conventional assessment, and the 95% CI. A higher point estimate represents better agreement between the methodologies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8","spread":null}]}]}]},{"type":"SECONDARY","title":"68Ga-PSMA-11 PET/CT Predictive Value by Region","description":"Positive predictive value (PPV) is the probability that participants with a positive screening test truly have the disease, and negative predictive value (NPV) is the probability that participants with a negative screening test truly do not have the disease. Predictive Value for 68Ga-PSMA-11 PET/CT was assessed by evaluating scans of the prostate, pelvic lymph nodes, paraaortic lymph nodes, mediastinal lymph nodes, bone, and lung. The outcome is reported as the probability as a percentage and the 95% CI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall 68Ga-PSMA-11 PET/CT Scan Quality Stratified by PSA Level","description":"Scan quality was assessed by sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) determinations for the 68Ga-PSMA-11 PET/CT scans in participants stratified by prostate-specific antigen (PSA) level in ng/mL. Stratification levels were as follows.\n\n* 0.2 to \\< 0.5\n* 0.5 to \\< 1.0\n* 1.0 to \\< 2.0\n* 2.0 to \\< 5.0\n* ≥ 5.0, The outcome is expressed as the Sensitivity, Specificity, PPV, and NPV values observed for the PSA level strata, with 95% confidence interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"82.1","spread":null},{"groupId":"OG004","value":"84.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"75.0","spread":null},{"groupId":"OG004","value":"74.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":[]}}}